摘要
目的 :探讨分析重组组织型纤溶酶原激活剂(rt-PA)静脉溶栓治疗急性脑梗死的临床疗效。方法 :选择2016年6月~2017年4月我院收治的134例急性脑梗死患者为研究对象,根据随机数表法分为对照组和观察组,各67例。对照组给予患者口服阿司匹林治疗,观察组则加用重组组织型纤溶酶原激活剂(rt-PA)进行溶栓治疗。评价两组临床疗效,并对比治疗前后两组患者日常生活能力、脑血管指标[脑血流量(Cerebral blood flow,CBF)、脑血容量(Cerebral blood volume,CBV)]及药物安全性。结果 :治疗后,观察组治疗总有效率92.54%(62/67)高于对照组的73.13%(49/67),差异有统计学意义;两组治疗后Barthel指数评分均高于治疗前,且观察组Barthel指数评分高于对照组,差异有统计学意义;治疗前,两组患者的脑血管血流动力学指标(CBF、CBV)差异无统计学意义;治疗后两组患者CBF、CBV水平均高于治疗前,且观察组高于对照组,差异有统计学意义。治疗期间,两组患者牙龈出血、脑出血、胃肠反应等不良反应总发生率比较[5.97%(4/67)vs 4.48%(3/67)],差异无统计学意义。结论 :在急性脑梗死患者中加用重组组织型纤溶酶原激活剂(rt-PA)进行溶栓治疗疗效显著,安全性高,可减轻患者神经功能损害,提高日常生活能力。
Objective To investigate the clinical efficacy of recombinant tissue plasminogen activator(rt-PA) intravenous thrombolysis in the treatment of acute cerebral infarction. Methods 134 cases of patients with acute cerebral infarction from June 2016 to April 2017 were selected as the object of this study. All the patients were divided into control group and observation group according to random number table method. In the control group, patients were treated with oral aspirin, Patients in the observation group were treated with thrombolytic therapy with recombinant tissue plasminogen activator(rt-PA). The clinical efficacy was evaluated and the improvement of daily living ability and drug safety were compared between the two groups before and after treatment. Results After treatment, the total effective rate was 92.54%(62/67) in the observation group and 73.13%(49/67) in the control group. The scores of Barthel index in the two groups were higher than those before treatment, and the Barthel index of the observation group was higher than that of the control group. There was no significant difference in cerebrovascular hemodynamics(CBF, CBV) between the two groups before treatment. The levels of CBF and CBV in the two groups were higher than those before treatment, and the observation group was higher than the control group. During the treatment period, the total incidence of adverse reactions such as gingival bleeding, cerebral hemorrhage, gastrointestinal reactions and other adverse reactions was not significant [5.97%(4/67) vs 4.48%(3/67) ]. Conclusion Patients with acute cerebral infarction to give recombinant tissue plasminogen activator thrombolytic therapy for significant efficacy, high safety, can reduce the patient's neurological damage, improve daily living ability.
出处
《湖南师范大学学报（医学版）》
2018年第4期187-189,共3页
Journal of Hunan Normal University(Medical Sciences)
